ENOVA is a science and technology “Network on Vaccine Adjuvants”, funded by COST through the EU Framework Programme Horizon 2020. ENOVA is coordinated by the Vaccine Formulation Institute (UK) and brings together European experts and stakeholders working in different areas of adjuvant and vaccine R&D, including both prophylactic and therapeutic applications as well as human and veterinary vaccines. ENOVA’s members include industry, academic, and government institutions. The ultimate goals of the network are to facilitate communication and the exchange of information among its membership, to ensure that new discoveries are widely disseminated so that their potential can be of optimal benefit, to promote the best use of existing adjuvant technologies, and to encourage and support the development of novel adjuvants.
Open Calls for TRANSVAC2 Vaccine Development Services. Deadline 15 january 2022
Dec. 10, 2021 9:19 AM
Remember to apply for TRANSVAC2 Vaccine Development Services before 15 January 2022
Adjuvant and Formulation training course
Dec. 2, 2021 11:03 PM
Sign up for a new training course in adjuvants and formulation March 21-22, 2022 in Geneva Switzerland
More info here
Oct. 13, 2021 10:04 AM
ENOVA STRATEGY ON VIRTUAL NETWORKING
Brankica Filipic has been awarded with VN Grant and to represent ENOVAs plans for virtual activities.
Adjuvants - the unsung heroes of vaccines
Sep. 17, 2021 9:39 AM
Article by ENOVA member Anita Milicic about the history of adjuvants
Adjuvant and formulation training
The next adjuvant training course, which is co-organized by ENOVA and TRANSVAC2, will take place from the 21st-24th of March 2022 in Geneva, Switzerland.
15th of December 2021
More info here